FogPharma

FogPharma is developing a new class of drugs to address the limitations of today’s precision medicines and achieve universal druggability. The company is pioneering the discovery, development and commercialization of Helicon™ peptides, a new drug modality that uniquely combines the broad targeting power of monoclonal antibodies with the cell-penetrating ability of small molecules. Helicon™ peptides show promise, not only to drug nearly all human disease drivers, but also to do so with unrivaled speed and scalability.